Apply This IPO

Best Margin

Zero Brokerage

24*7 Customer Support.

Fastest mobile support

---

Apply with Angel One

Apply with Zerodha

Pre-Apply with Upstox

Kronox Lab Sciences Limited IPO Review

Kronox Lab Sciences Limited IPO was engaged in manufacturing high-purity specialty chemicals used in various industries. Their chemicals are primarily used for (i) making Active Pharmaceutical Ingredients (APIs); (ii) as additives in pharmaceutical products; (iii) as reagents in scientific research and lab testing; (iv) as ingredients in nutraceutical products; (v) as intermediates and fermenting agents in biotech applications; (vi) as ingredients in agrochemical products; (vii) as components in personal care products; (viii) as refining agents in metal refining; and (ix) as ingredients in animal health products, among other uses.

They believe that their leaders' experience and diverse backgrounds have helped their company grow in domestic and international markets. Their industry knowledge allows them to predict and respond to market trends, manage and expand their operations, maintain strong customer relationships, and adapt to changing customer preferences.

Kronox Lab Sciences Limited Products and Services

Kronox Lab Sciences Limited Products and services are produce their products according to industry standards such as IP, BP, EP, JP, USP, FCC, LR, AR, GR, and ACS. Additionally, they offer custom manufacturing to meet specific customer requirements. Their high-purity specialty fine chemicals come in various grades and particle sizes, ranging from 10 mesh to 100 mesh.

Their Strengths are Wide range of products finding applications in diversified end-user industries, Long standing relationships with customers, High entry and exit barriers due to long customer approval cycles and strict product standards, Focus on R&D and Quality Control, Zero debt company with strong and consistent financial performance,

Financial Overview

The company operates in the high-purity specialty chemical sector and has a near-monopoly on some products. It currently offers 185 products, with another 122 in development. Considering the annualized earnings for FY24, the investment seems fairly valued. Investors might consider investing for medium to long-term gains.